TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.144nMAssay Description:Table 11: The experiments were performed on Biacore S200 (Cytiva). Biotinylated, unphosphorylated MEK1 was diluted to 0.1 uM by SPR buffer C (20 mM T...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.350nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.350nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.350nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.370nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.370nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.370nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.380nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.380nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.380nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.420nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.420nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.420nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.470nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.470nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.470nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.480nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.480nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.480nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.510nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.510nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.510nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.510nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.510nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.510nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.570nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.570nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.570nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 1nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1(Human)
Chugai Seiyaku Kabushiki Kaisha
US Patent
Chugai Seiyaku Kabushiki Kaisha
US Patent
Affinity DataIC50: 1nMAssay Description:The MEK1-inhibiting activity of the compounds listed in Table 3 below were evaluated by the fluorescent polarization method as described below.The te...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 1nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1(Human)
Chugai Seiyaku Kabushiki Kaisha
US Patent
Chugai Seiyaku Kabushiki Kaisha
US Patent
Affinity DataIC50: 1nMAssay Description:The MEK1-inhibiting activity of the compounds listed in Table 3 below were evaluated by the fluorescent polarization method as described below.The te...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 1nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1(Human)
Chugai Seiyaku Kabushiki Kaisha
US Patent
Chugai Seiyaku Kabushiki Kaisha
US Patent
Affinity DataIC50: 1nMAssay Description:The MEK1-inhibiting activity of the compounds listed in Table 3 below were evaluated by the fluorescent polarization method as described below.The te...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 1nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 1nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 1nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 1nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 1nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1(Human)
Chugai Seiyaku Kabushiki Kaisha
US Patent
Chugai Seiyaku Kabushiki Kaisha
US Patent
Affinity DataIC50: 1nMAssay Description:The MEK1-inhibiting activity of the compounds listed in Table 6 below were evaluated by the fluorescent polarization method as described below. The t...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1(Human)
Chugai Seiyaku Kabushiki Kaisha
US Patent
Chugai Seiyaku Kabushiki Kaisha
US Patent
Affinity DataIC50: 1nMAssay Description:The MEK1-inhibiting activity of the compounds listed in Table 6 below were evaluated by the fluorescent polarization method as described below. The t...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 1nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1(Human)
Chugai Seiyaku Kabushiki Kaisha
US Patent
Chugai Seiyaku Kabushiki Kaisha
US Patent
Affinity DataIC50: 2nMAssay Description:The MEK1-inhibiting activity of the compounds listed in Table 3 below were evaluated by the fluorescent polarization method as described below.The te...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1(Human)
Chugai Seiyaku Kabushiki Kaisha
US Patent
Chugai Seiyaku Kabushiki Kaisha
US Patent
Affinity DataIC50: 2nMAssay Description:The MEK1-inhibiting activity of the compounds listed in Table 3 below were evaluated by the fluorescent polarization method as described below.The te...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1(Human)
Chugai Seiyaku Kabushiki Kaisha
US Patent
Chugai Seiyaku Kabushiki Kaisha
US Patent
Affinity DataIC50: 2nMAssay Description:The MEK1-inhibiting activity of the compounds listed in Table 3 below were evaluated by the fluorescent polarization method as described below.The te...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1(Human)
Chugai Seiyaku Kabushiki Kaisha
US Patent
Chugai Seiyaku Kabushiki Kaisha
US Patent
Affinity DataIC50: 2nMAssay Description:The MEK1-inhibiting activity of the compounds listed in Table 3 below were evaluated by the fluorescent polarization method as described below.The te...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1(Human)
Chugai Seiyaku Kabushiki Kaisha
US Patent
Chugai Seiyaku Kabushiki Kaisha
US Patent
Affinity DataIC50: 2nMAssay Description:The MEK1-inhibiting activity of the compounds listed in Table 3 below were evaluated by the fluorescent polarization method as described below.The te...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1(Human)
Chugai Seiyaku Kabushiki Kaisha
US Patent
Chugai Seiyaku Kabushiki Kaisha
US Patent
Affinity DataIC50: 2nMAssay Description:The MEK1-inhibiting activity of the compounds listed in Table 6 below were evaluated by the fluorescent polarization method as described below. The t...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1(Human)
Chugai Seiyaku Kabushiki Kaisha
US Patent
Chugai Seiyaku Kabushiki Kaisha
US Patent
Affinity DataIC50: 2nMAssay Description:The MEK1-inhibiting activity of the compounds listed in Table 3 below were evaluated by the fluorescent polarization method as described below.The te...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1(Human)
Chugai Seiyaku Kabushiki Kaisha
US Patent
Chugai Seiyaku Kabushiki Kaisha
US Patent
Affinity DataIC50: 2nMAssay Description:The MEK1-inhibiting activity of the compounds listed in Table 6 below were evaluated by the fluorescent polarization method as described below. The t...More data for this Ligand-Target Pair

















